FWD1509 / Shenzhen Forward Pharma - LARVOL DELTA

Forward Pharma completed a Series A+ funding of ten millions CNY (EqualOcean) - "Shenzhen Forward Pharmaceutical Co., Ltd ('Forward Pharma') recently has announced the completion of ten millions of CNY in Series A+ funding....According to Forward Pharma, this round of financing will be mainly used for the clinical trials of non-small cell lung cancer (NSCLC) targeting drug FWD1509, and the clinical development of the third-generation oral selective estrogen receptor degrader (SERD) FWD1802 in breast cancer."

Financing • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Forward Pharmaceuticals Co., Ltd. | N=130 ➔ 30

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • HER-2

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2; N=130; Recruiting; Sponsor: Forward Pharmaceuticals Co., Ltd.

Clinical • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Forward Pharma’s 4th gen EGFR inhibitor FWD1509 approved for trials in China (GBI Health) - "The Center for Drug Evaluation (CDE) website indicates that Shenzhen Forward Pharmaceutical Co., Ltd’s Category 1 product FWD1509 MsOH has obtained clinical trial approval in advanced non-small cell lung cancer (NSCLC). FWD1509, an oral small molecule EGFR inhibitor, can efficiently penetrate the blood-brain barrier."

Non-US regulatory • Lung Cancer • Non Small Cell Lung Cancer • Oncology